Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
Status:
Completed
Trial end date:
2005-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the response rate of patients with T-cell
malignancies to combination therapy using interferon-alpha (Roferon) and Isotretinoin
(Accutane).